Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8615441 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 88 Pages |
Abstract
Our study found that the combination of GO with azacitidine is relatively well tolerated, with response rates similar to those with GO monotherapy at higher doses. Differences in the GO drug schedule, dose level, and frequency might explain the discrepant response rates between our study and others, suggesting that the optimal GO dose remains unclear, especially when combined with hypomethylating agent therapy.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Bruno C. Medeiros, Tiffany N. Tanaka, Larisa Balaian, Asad Bashey, Amy Guzdar, Hongying Li, Karen Messer, Edward D. Ball,